Has David Reesman received payments from drug or device companies?

Yes. Drug and device makers reported $8,546 in general payments to David Reesman across 82 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Reesman did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Reesman come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Reesman

Occupational Health · Wesley Chapel, FLNPI 1609369164

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,862, 2.8 times the $1,025 reported in 2022.

$8,546in general payments, 2019–2025

Across 82 payments — averaging $104.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$2K
Neurocrine Biosciences, Inc.$740
Abiomed$605
Amgen$605
Abbott$394
Sanofi Pasteur Inc.$374
plus $4K from 21 others

What the payments were for

Food & beverage$8,546100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	15	$1,519
Neurocrine Biosciences, Inc.	6	$740
Abiomed	6	$605
Amgen	5	$605
Abbott	4	$394
Sanofi Pasteur Inc.	4	$374
Boston Scientific	4	$365
Actelion Pharmaceuticals US, Inc.	3	$352
Sanofi	3	$346
Novo Nordisk	3	$344
Corcept Therapeutics	3	$343
Sanofi-aventis U.S. LLC	3	$327
AstraZeneca	3	$314
Insmed, Inc.	3	$300
Teva Pharmaceuticals USA, Inc.	2	$229
Arcutis Biotherapeutics, Inc.	2	$186
Bayer	2	$180
Cvrx, Inc.	1	$138
E.r. Squibb & Sons, L.L.C.	1	$128
Axonics, Inc.	2	$118
Argenx US, Inc.	1	$116
Alkermes, Inc.	1	$115
Paratek Pharmaceuticals, Inc.	1	$114
Boehringer Ingelheim	1	$101
Lucid Diagnostics Inc.	1	$100
Idorsia Pharmaceuticals US Inc	1	$62
Medtronic	1	$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few occupational health providers in Floridato place this figure against a meaningful peer group, so we don't.

Other occupational health in Wesley Chapel

Jean AertkerTampa$5K
Kathleen LaneSt Petersburg$2K
Laura LongTampa$662
Julia PattersonJacksonville$392
Karen CampbellOrlando$245
Joann SheaTampa$198
Rosemary OkochaTampa$51
Yoira SanchezLive Oak$27
Elizabeth NashTallahassee$23

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →